West Virginia University, School of Medicine, Rockefeller Neuroscience Institute, Department of Behavioral Medicine and Psychiatry, 930 Chestnut Ridge Road, Morgantown, West Virginia, United States; West Virginia University, School of Medicine, Department of Neuroscience, United States.
West Virginia University, School of Medicine, Rockefeller Neuroscience Institute, Department of Behavioral Medicine and Psychiatry, 930 Chestnut Ridge Road, Morgantown, West Virginia, United States; West Virginia University, School of Medicine, Department of Neuroscience, United States.
J Neurol Sci. 2020 Apr 15;411:116712. doi: 10.1016/j.jns.2020.116712. Epub 2020 Feb 3.
The United States continues to experience an opioid epidemic of unprecedented proportions despite FDA approval of life saving medications, such as buprenorphine. This paper describes a novel group-based buprenorphine treatment model and summarizes patient characteristics and treatment retention. This model, known as the Comprehensive Opioid Addiction Treatment (COAT) program, was developed in West Virginia, the epicenter of the opioid epidemic.
Data on 454 patients actively enrolled in the COAT program were extracted from an administrative clinical data set and electronic medical records and analyzed using descriptive and quantitative analysis to determine long-term retention in treatment using frequencies and means.
The characteristics of the 454 patients are as follows: average age of 39, 53% female, predominantly white (94%) and Medicaid was the primary insurance provider (68%). Analysis of retention showed 37.8% of patents were retained less than one year and 14.7% were retained 10 or more years. Initiating treatment at a younger age was associated with long-term retention.
Opioid use disorder is a chronic relapsing disease and treatment models that retain patients long-term have the greatest benefit. The COAT model has been successful in retaining patients long-term in a rural setting where barriers to treatment are many.
尽管食品和药物管理局批准了救命药物，如丁丙诺啡，但美国仍在经历一场前所未有的阿片类药物泛滥。本文描述了一种新型的基于团体的丁丙诺啡治疗模式，并总结了患者特征和治疗保留情况。这种模式被称为综合阿片类药物成瘾治疗（COAT）项目，是在阿片类药物泛滥的中心西弗吉尼亚州开发的。
从行政临床数据集中提取了 454 名积极参加 COAT 项目的患者的数据，并使用描述性和定量分析对电子病历进行了分析，以确定使用频率和平均值来确定长期治疗保留率。
454 名患者的特征如下：平均年龄 39 岁，53%为女性，以白人为主（94%），医疗补助是主要的保险提供者（68%）。保留率分析显示，37.8%的患者保留时间不到一年，14.7%的患者保留时间为 10 年或更长时间。在年轻时开始治疗与长期保留有关。
阿片类药物使用障碍是一种慢性复发性疾病，长期保留患者的治疗模式最有益。COAT 模式在治疗障碍众多的农村地区成功地长期保留了患者。
